MovDisordV3, PascalFrancis, Corpus, bibRecord, 000C90

Serial Volumetric MRI in Parkinsonian Disorders

Identifieur interne : 000C90 ( PascalFrancis/Corpus ); précédent : 000C89; suivant : 000C91

Serial Volumetric MRI in Parkinsonian Disorders

Auteurs : Edward J. Wild ; Nick C. Fox

Source :

Movement disorders [ 0885-3185 ] ; 2009.

RBID : Pascal:10-0038100

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Démence à corps de Lewy, Atrophie multisystématisée, Pathologie du système nerveux, Imagerie RMN.

English descriptors

KwdEn :
- Lewy body dementia, Multiple system atrophy, Nervous system diseases, Nuclear magnetic resonance imaging, Parkinson disease.

Abstract

Tracking progression in neurodegenerative diseases is hampered by the limitations of the clinical rating scales, which are seldom linear, suffer from floor and ceiling effects, lack the ability to distinguish symptomatic change from disease modification, and are limited by imperfect intra- and inter-rater reliability. The promise of an era of neuroprotective therapies renders urgent the search for reliable measures of progression. Biomarkers have the potential to enhance several aspects of both therapeutic trials and clinical practice. MRI-based measures of cerebral volume can provide a surrogate for neuronal loss and several techniques have been applied to elucidate disease processes, aid diagnosis, and enable monitoring of progression in a variety of Parkinsonian disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy and Huntington's disease. We review the approaches to, and findings revealed by, serial volumetric MRI in these disorders.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 24`
A06				`@2 14 @3 SUP`
A08	`01`	`1`	`ENG`	`@1 Serial Volumetric MRI in Parkinsonian Disorders`
A09	`01`	`1`	`ENG`	`@1 Imaging in Parkinson's Disease`
A11	`01`	`1`		`@1 WILD (Edward J.)`
A11	`02`	`1`		`@1 FOX (Nick C.)`
A12	`01`	`1`		`@1 POEWE (Werner) @9 ed.`
A12	`02`	`1`		`@1 SCHERFLER (Christopher) @9 ed.`
A14	`01`			`@1 Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurologyl National Hospital for Neurology and Neurosurgery, Queen Square @2 London @3 GBR @Z 1 aut. @Z 2 aut.`
A15	`01`			`@1 Department of Neurology, Innsbruck Medical University @2 Innsbruck @3 AUT @Z 1 aut. @Z 2 aut.`
A20				`@2 S691-S698`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000171427130060`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 52 ref.`
A47	`01`	`1`		`@0 10-0038100`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Tracking progression in neurodegenerative diseases is hampered by the limitations of the clinical rating scales, which are seldom linear, suffer from floor and ceiling effects, lack the ability to distinguish symptomatic change from disease modification, and are limited by imperfect intra- and inter-rater reliability. The promise of an era of neuroprotective therapies renders urgent the search for reliable measures of progression. Biomarkers have the potential to enhance several aspects of both therapeutic trials and clinical practice. MRI-based measures of cerebral volume can provide a surrogate for neuronal loss and several techniques have been applied to elucidate disease processes, aid diagnosis, and enable monitoring of progression in a variety of Parkinsonian disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy and Huntington's disease. We review the approaches to, and findings revealed by, serial volumetric MRI in these disorders.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B24A06`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Démence à corps de Lewy @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Lewy body dementia @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Demencia cuerpos Lewy @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Atrophie multisystématisée @2 NM @5 03`
C03	`03`	`X`	`ENG`	`@0 Multiple system atrophy @2 NM @5 03`
C03	`03`	`X`	`SPA`	`@0 Atrofia multisistematizada @2 NM @5 03`
C03	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 04`
C03	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 04`
C03	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 04`
C03	`05`	`X`	`FRE`	`@0 Imagerie RMN @5 09`
C03	`05`	`X`	`ENG`	`@0 Nuclear magnetic resonance imaging @5 09`
C03	`05`	`X`	`SPA`	`@0 Imaginería RMN @5 09`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 025`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0038100 INIST
ET :	Serial Volumetric MRI in Parkinsonian Disorders
AU :	WILD (Edward J.); FOX (Nick C.); POEWE (Werner); SCHERFLER (Christopher)
AF :	Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurologyl National Hospital for Neurology and Neurosurgery, Queen Square/London/Royaume-Uni (1 aut., 2 aut.); Department of Neurology, Innsbruck Medical University/Innsbruck/Autriche (1 aut., 2 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 14 SUP; S691-S698; Bibl. 52 ref.
LA :	Anglais
EA :	Tracking progression in neurodegenerative diseases is hampered by the limitations of the clinical rating scales, which are seldom linear, suffer from floor and ceiling effects, lack the ability to distinguish symptomatic change from disease modification, and are limited by imperfect intra- and inter-rater reliability. The promise of an era of neuroprotective therapies renders urgent the search for reliable measures of progression. Biomarkers have the potential to enhance several aspects of both therapeutic trials and clinical practice. MRI-based measures of cerebral volume can provide a surrogate for neuronal loss and several techniques have been applied to elucidate disease processes, aid diagnosis, and enable monitoring of progression in a variety of Parkinsonian disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy and Huntington's disease. We review the approaches to, and findings revealed by, serial volumetric MRI in these disorders.
CC :	002B17; 002B24A06
FD :	Maladie de Parkinson; Démence à corps de Lewy; Atrophie multisystématisée; Pathologie du système nerveux; Imagerie RMN
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Lewy body dementia; Multiple system atrophy; Nervous system diseases; Nuclear magnetic resonance imaging
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Demencia cuerpos Lewy; Atrofia multisistematizada; Sistema nervioso patología; Imaginería RMN
LO :	INIST-20953.354000171427130060
ID :	10-0038100

Links to Exploration step

Pascal:10-0038100

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Serial Volumetric MRI in Parkinsonian Disorders</title>
<author><name sortKey="Wild, Edward J" sort="Wild, Edward J" uniqKey="Wild E" first="Edward J." last="Wild">Edward J. Wild</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurologyl National Hospital for Neurology and Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fox, Nick C" sort="Fox, Nick C" uniqKey="Fox N" first="Nick C." last="Fox">Nick C. Fox</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurologyl National Hospital for Neurology and Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0038100</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 10-0038100 INIST</idno>
<idno type="RBID">Pascal:10-0038100</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C90</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Serial Volumetric MRI in Parkinsonian Disorders</title>
<author><name sortKey="Wild, Edward J" sort="Wild, Edward J" uniqKey="Wild E" first="Edward J." last="Wild">Edward J. Wild</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurologyl National Hospital for Neurology and Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fox, Nick C" sort="Fox, Nick C" uniqKey="Fox N" first="Nick C." last="Fox">Nick C. Fox</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurologyl National Hospital for Neurology and Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Lewy body dementia</term>
<term>Multiple system atrophy</term>
<term>Nervous system diseases</term>
<term>Nuclear magnetic resonance imaging</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Démence à corps de Lewy</term>
<term>Atrophie multisystématisée</term>
<term>Pathologie du   système nerveux</term>
<term>Imagerie RMN</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Tracking progression in neurodegenerative diseases is hampered by the limitations of the clinical rating scales, which are seldom linear, suffer from floor and ceiling effects, lack the ability to distinguish symptomatic change from disease modification, and are limited by imperfect intra- and inter-rater reliability. The promise of an era of neuroprotective therapies renders urgent the search for reliable measures of progression. Biomarkers have the potential to enhance several aspects of both therapeutic trials and clinical practice. MRI-based measures of cerebral volume can provide a surrogate for neuronal loss and several techniques have been applied to elucidate disease processes, aid diagnosis, and enable monitoring of progression in a variety of Parkinsonian disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy and Huntington's disease. We review the approaches to, and findings revealed by, serial volumetric MRI in these disorders.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>14</s2>
<s3>SUP</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Serial Volumetric MRI in Parkinsonian Disorders</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Imaging in Parkinson's Disease</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>WILD (Edward J.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FOX (Nick C.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>POEWE (Werner)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>SCHERFLER (Christopher)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurologyl National Hospital for Neurology and Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA15>
<fA20><s2>S691-S698</s2>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000171427130060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>52 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0038100</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Tracking progression in neurodegenerative diseases is hampered by the limitations of the clinical rating scales, which are seldom linear, suffer from floor and ceiling effects, lack the ability to distinguish symptomatic change from disease modification, and are limited by imperfect intra- and inter-rater reliability. The promise of an era of neuroprotective therapies renders urgent the search for reliable measures of progression. Biomarkers have the potential to enhance several aspects of both therapeutic trials and clinical practice. MRI-based measures of cerebral volume can provide a surrogate for neuronal loss and several techniques have been applied to elucidate disease processes, aid diagnosis, and enable monitoring of progression in a variety of Parkinsonian disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy and Huntington's disease. We review the approaches to, and findings revealed by, serial volumetric MRI in these disorders.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B24A06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Démence à corps de Lewy</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Lewy body dementia</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Demencia cuerpos Lewy</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Atrophie multisystématisée</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Multiple system atrophy</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Atrofia multisistematizada</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Imagerie RMN</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nuclear magnetic resonance imaging</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Imaginería RMN</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>025</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0038100 INIST</NO>
<ET>Serial Volumetric MRI in Parkinsonian Disorders</ET>
<AU>WILD (Edward J.); FOX (Nick C.); POEWE (Werner); SCHERFLER (Christopher)</AU>
<AF>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurologyl National Hospital for Neurology and Neurosurgery, Queen Square/London/Royaume-Uni (1 aut., 2 aut.); Department of Neurology, Innsbruck Medical University/Innsbruck/Autriche (1 aut., 2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 14 SUP; S691-S698; Bibl. 52 ref.</SO>
<LA>Anglais</LA>
<EA>Tracking progression in neurodegenerative diseases is hampered by the limitations of the clinical rating scales, which are seldom linear, suffer from floor and ceiling effects, lack the ability to distinguish symptomatic change from disease modification, and are limited by imperfect intra- and inter-rater reliability. The promise of an era of neuroprotective therapies renders urgent the search for reliable measures of progression. Biomarkers have the potential to enhance several aspects of both therapeutic trials and clinical practice. MRI-based measures of cerebral volume can provide a surrogate for neuronal loss and several techniques have been applied to elucidate disease processes, aid diagnosis, and enable monitoring of progression in a variety of Parkinsonian disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy and Huntington's disease. We review the approaches to, and findings revealed by, serial volumetric MRI in these disorders.</EA>
<CC>002B17; 002B24A06</CC>
<FD>Maladie de Parkinson; Démence à corps de Lewy; Atrophie multisystématisée; Pathologie du   système nerveux; Imagerie RMN</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Lewy body dementia; Multiple system atrophy; Nervous system diseases; Nuclear magnetic resonance imaging</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Demencia cuerpos Lewy; Atrofia multisistematizada; Sistema nervioso patología; Imaginería RMN</SD>
<LO>INIST-20953.354000171427130060</LO>
<ID>10-0038100</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C90 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000C90 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0038100
   |texte=   Serial Volumetric MRI in Parkinsonian Disorders
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Serial Volumetric MRI in Parkinsonian Disorders

Serial Volumetric MRI in Parkinsonian Disorders

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri